ONCOSEC MEDICAL Inc Form 8-K October 30, 2015

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 29, 2015

OncoSec Medical Incorporated

(Exact name of registrant as specified in its charter)

Nevada
(State or other jurisdiction of incorporation)

000-54318 (Commission File Number)

98-0573252 (I.R.S. Employer Identification No.)

5820 Nancy Ridge Drive
San Diego, CA
(Address of principal executive offices)

92121 (Zip Code)

Registrant $\,$ s telephone number, including area code: (855) 662-6732

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01	Entry into a Material Definitive Agreement.

Executive Employment Agreement with Chief Legal and Compliance Officer

On October 29, 2015, OncoSec Medical Incorporated (the Company) approved entering into customary indemnification agreements with its directors and executive officers. Current directors and executive officers are entering into such agreements on or about October 30, 2015, and future directors and executive officers may enter into such agreements from time to time.

The indemnification agreements will require the Company to indemnify its directors and executive officers (each, an Indemnitee) to the fullest extent permitted by Nevada law for certain liabilities to which an Indemnitee may become subject as a result of his or her affiliation or status with the Company. The indemnification agreements will also provide for advancement of an Indemnitee s expenses.

The foregoing description of the form of indemnification agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the form of indemnification agreement, which is attached as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

1

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

10.1 Form of Indemnification Agreement for directors and officers of OncoSec Medical Incorporated

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 30, 2015 OncoSec Medical Incorporated

By: /s/ Punit Dhillon

Name: Punit Dhillon

Title: President and Chief Executive Officer

(Principal Executive Officer)

2

EXHIBIT INDEX

Exhibit	Description
10.1	Form of Indemnification Agreement for directors and officers of OncoSec Medical Incorporated